From our survey

Commercially insured and never heard of Spravato

You have a good job with a real health plan. You pay the premium every paycheck. You have been through two antidepressants, and you still feel flat. And there is a reasonable chance that a treatment your plan might cover, one the FDA approved precisely for depression that standard medication leaves in place, has never once been mentioned to you.

That is not a guess. It is what our survey suggests about how little the public knows, and it has particular consequences for people with employer or other commercial coverage, who often have more options than they realize.

The awareness number

We commissioned a Pollfish consumer panel survey of 443 Midwesterners aged 18 to 64, which closed in June 2026. We asked how familiar people were with Spravato, an esketamine product taken as a nasal spray.

• Never heard of it: 73 percent
• Heard the name, not sure what it is: 21 percent
• Know what it is: 6 percent

Put another way, for every person who could explain the treatment, about twelve had never encountered it at all. Each is a whole-sample, top-line share, and each comes out of Pollfish's validated export.

Who holds commercial coverage

We also asked what kind of health coverage respondents had, allowing more than one answer. Commercial insurance, which includes employer plans and individually purchased plans, was reported by 39 percent, the largest single group. Medicaid was close behind at 37 percent, followed by Medicare at 23 percent.

We want to be precise about what we can and cannot say. The final validated data does break awareness out by coverage type. Take the 173 respondents who carry commercial insurance: Spravato was a name they had never encountered in 74 percent of cases, essentially the same blank as the sample overall. A plan card, in other words, came with no extra knowledge of the treatment. That commercially insured group also leaned hard on physicians: 81 percent said their own doctor's recommendation would move them most.

Why the gap matters more with a commercial plan

Esketamine's FDA approval applies to adults whose depression is treatment-resistant, which usually means two or more antidepressant trials have fallen short. Many commercial plans cover it for patients who meet their criteria, usually with prior authorization. That means a meaningful number of people may be paying for coverage of a treatment they do not know exists. This overview of Spravato and its coverage lays out the basics.

Coverage clearly matters to people. For 85 percent of our respondents, insurance coverage was one of the two provider traits that mattered most, and 65 percent said coverage would weigh as deciding or big in trying the treatment. And just over half said they would rather go through their insurance with more hoops than pay themselves for a simpler path.

How people would find out

Most respondents would not go looking on their own. When asked where they would turn first, 56 percent said their primary care doctor and 23 percent a psychiatrist. And when asked what would actually persuade them to try the treatment, 74 percent pointed to their own doctor's recommendation, compared with 2 percent for advertising.

We also asked people for the words they would put in a search bar when seeking help, and they wrote things like "depression medicine alternatives." Nobody typed a drug name. A treatment you have never heard of is not a treatment you can search for.

What to do if you have commercial insurance

This is where the data story turns practical. If standard antidepressants have not worked for you and you carry an employer or marketplace plan:

• Raise it with your doctor. Ask: "I have tried these medications without enough improvement. Does that count as treatment-resistant depression, and is esketamine something to consider?"
• Find your plan's policy. Many insurers publish clinical coverage policies online. Search your insurer's site for "esketamine" or "Spravato" to see what criteria they use.
• Call member services. Ask whether esketamine is covered, whether prior authorization is required, whether it runs through your medical benefit or pharmacy benefit, and which certified treatment centers near you are in network.
• Check your cost sharing. Deductibles and coinsurance can make early visits more expensive than later ones. Ask what your out-of-pocket maximum is.
• Ask about support programs. The manufacturer runs a patient support program, and cost-support options have been available to some commercially insured patients. Eligibility rules apply, and government insurance is typically excluded.
• Keep records. A dated list of every antidepressant you have taken, with doses, is often what a prior authorization hinges on.

What to know before starting

Esketamine is not a take-home prescription. It is self-administered in the nose, under staff supervision, at a certified treatment center, followed by a monitoring period. You cannot drive until the next day, so you will need a ride. Early treatment involves more frequent visits. For people in the Midwest, where a certified center may be a long drive, that matters. Forty-three percent of our respondents made nearness to home one of their two biggest priorities.

It is also not the same as at-home ketamine sold by some telehealth companies. Those programs use ketamine off-label, often on a cash-pay basis, with far less supervision. Commercial plans are less likely to cover them. Do not assume that because one is covered, the other is.

Your health history decides whether esketamine is right for you, and a clinician is the one to judge it.

The bottom line

Most people do not know this treatment exists. A large share of people have commercial coverage that may pay for it when criteria are met. Closing that gap usually takes one conversation with a doctor and one phone call to an insurer.

Anyone in a dark place right now should skip all of that and reach out today. Wherever you are in the country, whatever the time, a call or text to 988 is picked up by the Suicide and Crisis Lifeline; veterans who call can press 1. It costs nothing and has nothing to do with your insurance.

Methodology

Pollfish consumer panel, 443 completed responses, fieldwork ending June 23, 2026, respondents aged 18 to 64 living in Indiana, Wisconsin, Kansas, Illinois, Missouri, Oklahoma, Minnesota, Iowa, Nebraska, and Ohio. Whole-sample figures are top-line, the commercial-insurance figures come from the group breakdown named above, multiple payer answers were allowed, and every figure is from the final validated data. The publisher both ordered and funded this research. Coverage details vary by plan; this is not medical or insurance advice.